Similar articles for PMID: 23376290

Year	Number of Results
1912	1
2000	1
2002	4
2003	5
2004	2
2005	2
2006	1
2007	7
2008	10
2009	7
2010	20
2011	20
2012	22
2013	25
2014	22
2015	20
2016	16
2017	14
2018	12
2019	10
2020	6
2021	12
2022	8
2023	3
2024	0

1

Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease.

Gutiérrez A, Scharl M, Sempere L, Holler E, Zapater P, Almenta I, González-Navajas JM, Such J, Wiest R, Rogler G, Francés R. Gutiérrez A, et al. Gut. 2014 Feb;63(2):272-80. doi: 10.1136/gutjnl-2012-303557. Epub 2013 Feb 1. Gut. 2014. PMID: 23376290 Free article.

2

Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn's disease.

Juanola O, Moratalla A, Gutiérrez A, Sempere L, Zapater P, Giménez P, Almenta I, Peiró G, González-Navajas JM, Such JF, Francés R. Juanola O, et al. J Gastroenterol. 2015 Jul;50(7):758-68. doi: 10.1007/s00535-014-1020-5. Epub 2014 Dec 11. J Gastroenterol. 2015. PMID: 25500977

3

Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients With Crohn's Disease.

Gutiérrez A, Zapater P, Juanola O, Sempere L, García M, Laveda R, Martínez A, Scharl M, González-Navajas JM, Such J, Wiest R, Rogler G, Francés R. Gutiérrez A, et al. Am J Gastroenterol. 2016 Apr;111(4):529-40. doi: 10.1038/ajg.2016.8. Epub 2016 Feb 23. Am J Gastroenterol. 2016. PMID: 26902226 Free article.

4

Pattern recognition receptor and autophagy gene variants are associated with development of antimicrobial antibodies in Crohn's disease.

Murdoch TB, Xu W, Stempak JM, Landers C, Targan SR, Rotter JI, Silverberg MS. Murdoch TB, et al. Inflamm Bowel Dis. 2012 Sep;18(9):1743-8. doi: 10.1002/ibd.22884. Epub 2012 Jan 24. Inflamm Bowel Dis. 2012. PMID: 22275320 Free PMC article.

5

Crohn's disease-associated ATG16L1 polymorphism modulates pro-inflammatory cytokine responses selectively upon activation of NOD2.

Plantinga TS, Crisan TO, Oosting M, van de Veerdonk FL, de Jong DJ, Philpott DJ, van der Meer JW, Girardin SE, Joosten LA, Netea MG. Plantinga TS, et al. Gut. 2011 Sep;60(9):1229-35. doi: 10.1136/gut.2010.228908. Epub 2011 Mar 15. Gut. 2011. PMID: 21406388

6

Monocyte-derived macrophages from Crohn's disease patients are impaired in the ability to control intracellular adherent-invasive Escherichia coli and exhibit disordered cytokine secretion profile.

Vazeille E, Buisson A, Bringer MA, Goutte M, Ouchchane L, Hugot JP, de Vallée A, Barnich N, Bommelaer G, Darfeuille-Michaud A. Vazeille E, et al. J Crohns Colitis. 2015 May;9(5):410-20. doi: 10.1093/ecco-jcc/jjv053. Epub 2015 Mar 24. J Crohns Colitis. 2015. PMID: 25805890

7

Mutations in the NOD2 gene are associated with a specific phenotype and lower anti-tumor necrosis factor trough levels in Crohn's disease.

Schäffler H, Geiss D, Gittel N, Rohde S, Huth A, Glass Ä, Brandhorst G, Jaster R, Lamprecht G. Schäffler H, et al. J Dig Dis. 2018 Nov;19(11):678-684. doi: 10.1111/1751-2980.12677. Epub 2018 Nov 28. J Dig Dis. 2018. PMID: 30284387

8

IL23R, NOD2/CARD15, ATG16L1 and PHOX2B polymorphisms in a group of patients with Crohn's disease and correlation with sub-phenotypes.

Lauriola M, Ugolini G, Rivetti S, Nanì S, Rosati G, Zanotti S, Montroni I, Manaresi A, Zattoni D, Belluzzi A, Castellani L, D'Uva G, Mattei G, Taffurelli M, Strippoli P, Solmi R. Lauriola M, et al. Int J Mol Med. 2011 Mar;27(3):469-77. doi: 10.3892/ijmm.2010.591. Epub 2010 Dec 27. Int J Mol Med. 2011. PMID: 21206965

9

Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease.

Zapater P, Almenara S, Gutiérrez A, Sempere L, García M, Laveda R, Martínez A, Scharl M, Cameo JI, Linares R, González-Navajas JM, Wiest R, Rogler G, Francés R. Zapater P, et al. Inflamm Bowel Dis. 2019 Jul 17;25(8):1357-1366. doi: 10.1093/ibd/izz012. Inflamm Bowel Dis. 2019. PMID: 30776076 Free article.

10

NOD2/CARD15 does not influence response to infliximab in Crohn's disease.

Vermeire S, Louis E, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, Pescatore P, Fiasse R, Pelckmans P, Vlietinck R, Merlin F, Zouali H, Thomas G, Colombel JF, Hugot JP; Belgian Group of Infliximab Expanded Access Program and Fondation Jean Dausset CEPH, Paris, France. Vermeire S, et al. Gastroenterology. 2002 Jul;123(1):106-11. doi: 10.1053/gast.2002.34172. Gastroenterology. 2002. PMID: 12105838 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

209 results

Results by year